Valuation: NetraMark Holdings Inc.

Market Cap 54.88M 39.1M 35.08M 32.44M 29.38M 3.72B 55.55M 388M 154M 1.95B 147M 144M 6.19B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 54.88M 39.1M 35.08M 32.44M 29.38M 3.72B 55.55M 388M 154M 1.95B 147M 144M 6.19B EV / Sales 2026 *
137x
EV / Sales 2027 * -
Free-Float
89.17%
Yield 2026 *
-
Yield 2027 * -
09-10 NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models CI
09-01 Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors CI
08-14 NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
07-09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-14 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-07 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
1 day+5.45%
1 week-1.69%
Current month-19.44%
1 month-14.71%
3 months-25.64%
6 months-35.56%
Current year-47.27%
1 week 0.48
Extreme 0.48
0.6
1 month 0.48
Extreme 0.48
0.76
Current year 0.48
Extreme 0.48
1.28
1 year 0.48
Extreme 0.48
1.29
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
1.97
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 16/02/2022
President - 03/07/2022
Director of Finance/CFO 57 17/07/2022
Director TitleAgeSince
Chairman 40 08/06/2025
Director/Board Member - -
Director/Board Member - 15/06/2022
Date Insider Type Main position Quantity % Market Cap. Importance
23/09/26 Buy

Chairman

10,000 0.0108%
23/09/26 Buy

Chairman

25,000 0.0270%
23/09/26 Buy

Chairman

25,000 0.0270%
Change 5-day change 1-year change 3-year change Capi.($)
+5.45%-1.69%-54.33%+46.84% 39.1M
-1.23%+0.26%-3.53%+54.89% 3,944B
-0.52%-0.44%-1.75%+1,229.68% 473B
-2.68%+11.29%-49.25%+37.45% 438B
-4.70%+6.39%+73.88%+216.57% 323B
-2.73%+9.48%+91.02%+496.76% 274B
-0.86%-2.79%-6.67%+66.68% 272B
-24.82%-27.77%-37.81%-0.28% 155B
-22.37%-21.92%+60.36%+139.80% 128B
-4.99%+3.39%+70.83%+231.41% 99.97B
Average -5.91%+3.37%+14.28%+251.98% 610.59B
Weighted average by Cap. -2.59%+1.70%+3.20%+176.78%

Financials

2026 *2027 *
Net sales 401K 286K 256K 237K 215K 27.21M 406K 2.83M 1.13M 14.24M 1.07M 1.05M 45.2M -
Net income - -
Net Debt - -
Projected Income Statement - Annual - NetraMark Holdings Inc.
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
28/10/26 CA$0.5800 +5.45% 32,300
27/10/26 CA$0.5500 +5.77% 7,601
23/10/26 CA$0.5200 +4.00% 134,300
22/10/26 CA$0.5000 -15.25% 101,708
21/10/26 CA$0.5900 0.00% 68,400

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - NetraMark Holdings Inc.
  1. Stock Market
  2. Stocks
  3. AIAI Stock